Isatuximab Plus Kd Yields Consistent PFS Benefit Vs Kd Alone in Relapsed Multiple Myeloma
Updated results from the phase 3 IKEMA study showed a progression-free survival benefit with the addition of isatuximab to carfilzomib and dexamethasone that was consistent with interim results in patients with relapsed multiple myeloma.